Items tagged with Research and development
2022 WGND Annual Meeting (post)
The Stop TB Partnership Working Group on New Drugs (WGND)’ Annual Meeting will take place virtually on 3 November 2022.
TB vaccine advocacy fellowship 2023 - APPLY NOW (post)
The TB Vaccine Advocacy Roadmap (TB Vax ARM) and the Stop TB Partnership Working Group on New TB Vaccines announced a new advocacy fellowship program, set to take place in February 2023 in the run up to World TB Day. The program will convene six fellows representing TB affected communities, advocates, and early career researchers from high TB burden countries for an online skill building and co-learning program. The goal of the program is to help cultivate a new generation of TB vaccine R&D advocates and stimulate more diverse advocacy efforts for TB vaccine R&D ahead of the UN High-Level Meeting on TB in September 2023 and beyond.
Innovation deficit: Funds for neglected diseases like TB are falling short (post)
NEW YORK (January 31, 2023)—The 2022 G-FINDER Report, released today, reveals that for the year 2021, global funding for the development of critical new health technologies to overcome the world’s deadliest neglected diseases remained woefully inadequate and largely stagnant. Specifically, global investments in tuberculosis (TB) research and development (R&D) totaled $723 million in 2021, comparable to last year’s total and far short of the $2.16 billion estimated by Stop TB Partnership as needed annually to develop and deliver the suite of drug regimens, vaccines, and diagnostics that can end the TB pandemic. TB is regaining its dubious distinction as the world’s deadliest infectious disease, with more than 10 million people afflicted and 1.6 million dying each year.
New TB vaccines needed to tackle AMR (post)
Tuberculosis (TB) is an airborne global pandemic that kills 1.6 million people each year, causes over 10 million people to fall sick, and poses catastrophic costs for patients and rising costs for health systems. The growing threat of drug-resistant TB is a major contributor to the global burden of antimicrobial resistance (AMR) and a significant cause of AMR deaths. New vaccines are urgently needed to tackle this crisis. Yet, despite the huge threat posed by drug-resistant TB, political and financial support falls dangerously short of what is needed to effectively address this threat.
Publication demonstrates how equitable deals for access to medicines can be signed with pharmaceutical industry (post)
12 Apr 2023 — A new article published today by the Oxford University Press Journal of Intellectual Property Law and Practice shows how fair deals on medical research that ensure equitable access to life-saving medicines can be signed with pharmaceutical companies.
Webinar: Results of consensus process on inclusion of children in TB diagnostics development and evaluation (post)
Over the last year, stakeholders from academia, industry, government, funding agencies, and advocacy groups completed a consensus process on how to include children and adolescents in TB diagnostic development and evaluation.
Germany issues award to IAVI to support development of the MTBVAC TB vaccine candidate (post)
NEW YORK — JULY 6, 2023 — IAVI is pleased to announce a new award has been granted by the German government to help support the late-stage development of a promising tuberculosis (TB) vaccine candidate, MTBVAC.
Why is the global threat of the TB pandemic continually neglected? (post)
TB is the second most infectious deadly disease after COVID-19, so why has it been met with political inertia? Vinny Wooding, Senior Parliamentary Advocacy Officer at RESULTS UK, discusses the burden of TB and the rapid action needed to address this global threat.
Webinar recording: Research & development #GameChangers to end TB (post)
A webinar, co-hosted by Stop TB Canada and Results Canada, provided an overview of the research & development (R&D) landscape for TB, including an assessment of how global TB R&D investments compare to the financial need identified in the new Global Plan to End TB.
TB Vax ARM virtual meeting: Prioritizing TB R&D at the UNHLM on TB and beyond (post)
With the United Nations High-Level Meeting (UNHLM) on TB just weeks away, the TB Vaccine Advocacy Roadmap (TB Vax ARM) will host a special meeting on TB research and development (R&D) advocacy in the run up to this milestone event.
Page 16 of 28 · Total posts: 0
←First 15 16 17 Last→